NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM โ 12 April 2017 โ Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Read More
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendiaโs MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrintยฎ is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial IRVINE, CA and AMSTERDAM, 21 March 2017 โ Agendia, a world leader in Read More
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendiaโs MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer IRVINE, CA and AMSTERDAM โ Read More